RT @YuHengLau: We're hiring!🚨Our lab @SydneyChemistry is looking for two new #chempostdoc for our drug discovery program: . 1) Synthetic/Me….

RT @esmecurbino: ESMEC 2025 URBINO - European School of Medicinal Chemistry: June 29 – July 3, 2025. Tentative Programme Available and REGI….

RT @rsc_medchem: On the issue 1 cover is work by Sabrina Taliani, Floriana Morgillo, @scoscona & co on the discovery of c-MET/SMO modulator….

RT @JCIM_JCTC: Discovering Dually Active Anti-cancer Compounds with a Hybrid AI-structure-based Approach #DrugDiscovery ..

Our manuscript is now featured on the front cover of @JCIM_JCTC!.Huge thanks to the talented @ben_nitro93 and @MicheleRoggia99 for creating this amazing cover art! #MyACSCover @ACS4Authors

RT @BiologyAIDaily: Discovering Dually Active Anti-cancer Compounds with a Hybrid AI-structure-based Approach @JCIM_JCTC . 1/ In this study….

RT @EuroMedChem: 📣 Session 9 – Prof. Sandro COSCONATI from @unicampania is now on the stage for talk titled “From Reversible to Irreversibl….

RT @g_sbardella: Next talk in the peptide session at #EFMCISMC24 is given by Sandro Cosconati (@scoscona), describing his strategy to induc….

RT @JCIM_JCTC: Streamlining Large Chemical Library Docking with Artificial Intelligence: the PyRMD2Dock Approach #Docking #DrugDiscovery.ht….

Take a peek at my cover art accepted for the 21 Dec issue of @CellChemBiol! Gratitude to @AIRC_it for supporting my research and shout-out to fellow authors @hildaApickett, @sadimaro80, and Alex Sobinoff. #drugdiscovery #CancerResearch

RT @CellChemBiol: Online now! Irreversible inhibition of TRF2TRFH recruiting functions by a covalent cyclic peptide induces telomeric repli….

Co-treatment with the G4 stabilizing agent RHPS4 amplifies APOD53's effects on telomeric replication stress, offering a potential combination strategy for cancer treatment. The interplay between TRFH targeting peptides and replication stress inducers is explored.

APOD53's impact goes beyond inhibiting TRF2; it blocks the interaction of RTEL1 and SLX4 with TRF2, inducing replication stress, DNA damage, and telomere fragility. This sets the stage for a robust telomeric DNA damage response.

APOD53, a cysteine-binding acrylamide Michael acceptor modifier, forms covalent adducts with the TRF2TRFH peptide. Compared to its predecessor APOD41, APOD53 emerges as a more potent inhibitor of cellular viability, especially in cancer cells.

Our work identified APOD41 as a cell-permeable TRF2 binder. To enhance its efficiency, we modified APOD41 derivatives with reactive species, turning them into covalent binders. The goal: disrupt TRF2 functions more effectively. #covalentmodifiers #drugdiscovery #drugdevelopment.

Telomeres play a pivotal role in cancer cell proliferation, making factors like TRF2 attractive targets for cancer therapies. Traditional telomere elongation inhibition faces challenges, leading us to explore a new avenue: targeting TRF2 function in cancer. #CancerResearch.

Our latest paper in @CellChemBiol unveils APOD53, an antiproliferative cyclic peptide co-discovered with @PicketHilda and @TheCesareLab to bind TRF2. Kudos to first authors @sadimaro80 and Alex Sobinoff! Special thanks to @AIRC_it for their support.

APOD53, a cysteine-binding acrylamide Michael acceptor modifier, forms covalent adducts with the TRF2TRFH peptide. Compared to its predecessor APOD41, APOD53 emerges as a more potent inhibitor of cellular viability, especially in cancer cells.

Our work identified APOD41 as a cell-permeable TRF2 binder. To enhance its efficiency, we modified APOD41 derivatives with reactive species, turning them into covalent binders. The goal: disrupt TRF2 functions more effectively. #covalentmodifiers #drugdiscovery #drugdevelopment.